InterventionsHumans

Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes

Nature Communications

The paper

Po-Yi Liu, Chao-Kuei Shih, Miyuki Hsing‐Chun Hsieh,

Ching‐Chun Lin, C L Liu, Edward Chia‐Cheng Lai, Chung‐Yi Li, Chih-Hen Yu,

Junne‐Ming Sung

National Cheng Kung University Hospital

Nature Communications · 30 Jul 2026

doi.org/10.1038/s41467-026-76083-5 PubMed 42669711

SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Neurology Genetics · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Drug Design, Development and Therapy · 5 Oct 2026